With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention. | At the Senate committee hearing on Novo Nordisk's prices for Ozempic and Wegovy,
Sanders says PBMs won’t penalize Novo for cutting Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders said major drug middlemen have agreed not to limit coverage of Novo Nordisk’s Ozempic and Wegovy if the company lowers the prices of the treatments. It’s Sanders’ latest move to pressure Novo to cut the prices of the blockbuster diabetes and obesity therapies.
The PBMs say out-of-pocket insulin costs have fallen sharply since 2019. The Pharmaceutical Care Management Association, ...
"All we are saying [to Novo Nordisk] is, Treat the American people the same way that you treat people all over the world.
Ted Okon, MBA, executive director of the Community Oncology Alliance, spoke with The American Journal of Managed Care® about how the Federal Trade Commission's (FTC) lawsuit against pharmacy benefit ...
In a move to address escalating insulin prices, the Federal Trade Commission (FTC) has initiated action against the three ...
The city of Baltimore's lawsuit contended Biogen paid the companies to “manipulate” placement of generic versions of ...
No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable ...
The US Federal Trade Commission said that CVS Health's Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum ...
The owner of one of the three largest pharmacy middlemen in the United States filed suit on Sept. 16 to quash an attempt by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback